[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"burn-pit-exposure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:burn-pit-exposure":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":37,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":5},"100639368","phase-2-use-of-bile-acid-binding-resins-to-decrease-pfas-levels-via-colesevalem-in-veterans-study-100639368",false,"NCT07592858","Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study","Use of Bile Acid Binding Resins to Decrease Systemic Per- and Polyfluoroalkyl Substance (PFAS) Levels and Improve Serum Lipid Profiles in Veterans: PFAS Reduction in Veterans Via Colesevalem Study (PAVERS) Study","PAVERS","Inclusion:\n\n* Male or female Veterans aged 25- 65 who have serum PFAS \\>20 ng\u002Fml exceeding National Academy of Science guidance.\n* Written informed consent will be obtained.\n* Outpatient.\n* Agreeable to participate in sharable data and biorepository.\n\nExclusion:\n\n* Under the age of 25 years\n* Unable or unwilling to sign the informed consent statement and HIPAA Authorization form\n* Females who are pregnant (confirmed by urine pregnancy test), nursing or planned pregnancy within study period.\n* Patients with hypertriglyceridemia, vitamin deficient patients, hyperthyroidism and diabetic, pancreatitis and intestinal and bowel obstruction\n* Be receiving any investigational drug other than Colesevelam or participating in any other investigational study.\n* Significant medical illnesses that may limit the subject's ability to complete follow-up visits, in the opinion of the investigator.\n* Be receiving any non-standard immunosuppression protocol or other non-standard treatment that could affect interpretation of the study results.\n* Those with significant cardiovascular disease including treatment with inotropes.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Active substance abuse if this, in the opinion of the investigator, will interfere with the subject's ability to adhere to the study protocol.",true,"ALL","25 Years","65 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this study is to test the efficacy and feasibility of Colesevelam administration (50% of the recommended dose) to reduce serum PFAS concentration in the Veteran population who have serum PFAS levels that exceed the National Academies Science criteria (PFASsix \\> 20 ng\u002Fml) using a double blind-placebo controlled study. Based on PFAS prevalence in serum samples, we anticipate recruiting up to n=500 Veterans to meet the goal of n=50 study participants to receive intervention or placebo. The primary outcome will be initial and final PFAS content in serum (total and 7 individual PFAS). The secondary outcome will be initial and final serum biomarkers related to lipid metabolism. As an exploratory aspect to the proposal, we will also measure fecal PFAS, bile acids, and microbial diversity to examine associations between PFAS content and bile acid levels and microbiome. Fecal PFAS, bile acid content, and microbiome may also be measured.",[29,30,31,32,33,34,35,36],"PFAS","Environmental Exposures","Occupational Exposure to Chemicals","Military Exposure","Burn Pit Exposure","Forever Chemicals","Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia","Hyperlipidemia (E.G., Hypercholesterolemia)",[29,38,39,40],"Military exposure","Forever chemicals","Colesevelam","NOT_YET_RECRUITING","2026-05-11",{"date":44,"type":45},"2026-05-18","ACTUAL",{"date":47,"type":23},"2026-07-01",{"date":49,"type":23},"2029-09-29",{"name":51,"class":52},"University of Rhode Island","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":17,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":74,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100636173","project-phoenix-molecular-signatures-of-burn-pit-exposure-100636173","NCT07562243","Project PHOENIX: Molecular Signatures of Burn Pit Exposure","Molecular, Genomic, Cellular, and Functional Characterization of Blood Specimens From Former U.S. Service Members With Prior Burn Pit Exposure","PHOENIX","Inclusion Criteria:\n\n* Age 18 years or older at the time of consent\n* Former or current U.S. Service Member, including Active Duty, Reserve, National Guard, or Veteran status\n* For exposed cohort: prior deployment to a location with known burn pit operations, based on participant report and available confirmation when feasible\n* For control cohort: no known deployment to burn pit locations\n* Able and willing to provide informed consent and HIPAA authorization\n* Willing to complete study questionnaires and donate venous blood sample\n* Able to complete study procedures in English or with approved translation support\n* Available for one baseline visit and optional future re-contact, if applicable\n\nExclusion Criteria:\n\n* Active serious illness or infection that, in the investigator's judgment, would compromise participation or specimen integrity\n* Receipt of systemic chemotherapy, immunotherapy, or radiation therapy within the past 6 months\n* High-dose systemic immunosuppression, defined as more than 20 mg prednisone equivalent daily for more than 14 days within the past 3 months\n* Pregnant or currently breast-feeding\n* Hemoglobin less than 10 g\u002FdL, known bleeding disorder, or platelet count less than 100 × 10\\^9\u002FL, if known\n* Severe psychiatric illness or other condition that impairs ability to provide informed consent\n* Prisoner or institutionalized individual\n* Prior participation in this or a related Project PHOENIX protocol\n* Any other condition that, in the investigator's judgment, may increase risk or interfere with study conduct or data integrity","18 Years",{"count":63,"type":23},1000,"5 Years","OBSERVATIONAL","Project PHOENIX is an observational clinical research study designed to characterize molecular, genomic, cellular, and functional features in blood specimens from former U.S. Service Members with prior burn pit exposure and from matched unexposed controls. Participants will complete screening, informed consent, health and exposure questionnaires, and a one-time blood collection. Blood-derived specimens may undergo genomic, epigenomic, transcriptomic, proteomic, metabolomic, immunophenotyping, and cellular functional analyses. Participants may also agree to optional future re-contact for health updates and possible repeat blood collection. The goal is to identify biologic signatures associated with prior deployment-related burn pit exposure and to support future biomarker discovery and translational research in veteran health.",[33,68,69,70,71,72,73],"Airborne Hazard Exposure","Veteran Health","Deployment-Related Toxic Exposure","Biomarkers","Immune Dysfunction","Respiratory Symptoms",[75,76,77,78,79,80,81,82,83,84,85,86,87],"Burn pit","Airborne hazards","Veterans","Deployment exposure","Multi-omics","PBMC","Biomarker discovery","Transcriptomics","Epigenomics","Proteomics","Metabolomics","Toxic exposure","Military service","2026-04-27",{"date":90,"type":45},"2026-05-01",{"date":90,"type":23},{"date":93,"type":23},"2031-12-31",{"name":95,"class":96},"Creative Medical Technology Holdings Inc","INDUSTRY",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":17,"sex":18,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":24,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100594363","tele-exercise-for-merp-100594363","NCT07018466","Tele-Exercise for MERP","Tele-Exercise in Veterans With Military Exposure","TEMPO","Inclusion Criteria:\n\n* Veteran\n* Age \\> or equal to 40 years\n* Self-reported exposure to burn pits and\u002For burn pit smoke during overseas military deployment (at least 6 hours per day during one or more deployments of at least three months)\n* ability to interact with study staff using video conferencing technology\n* ability to provide written informed consent\n\nExclusion Criteria:\n\n* Musculoskeletal or medical conditions which preclude participation in a tele-exercise program\n* Active severe mental health or psychiatric issues, including suicidality\n* Severe pulmonary disease (chronic supplemental oxygen), or lobectomy or greater resection\n* Myocardial infarction (within 3 months), or exertional or unstable angina\n* Uncontrolled systemic hypertension, defined as resting systolic blood pressure \\> 180 mmHg or diastolic blood pressure \\> 110 at time of most recent evaluation at time of recruitment\n* Active systemic treatment for cancer\n* Acute care hospitalization within the last 90 days\n* End-stage liver or renal disease\n* Any other medical or psychiatric condition that would preclude safe participation in tele-exercise, according to the judgment of the investigators","40 Years",{"count":107,"type":23},100,[109],"NA","During Operations Desert Shield and Desert Storm, Veterans in combat were exposed to a variety of airborne hazards, including oil well fire smoke, emissions from burn pits, and other substances associated with negative health outcomes, including cardiovascular and pulmonary disease and cancer. More than 40% of Veterans enrolled in the VA's Airborne Hazards and Open Burn Pit Registry (AHOBPR) report functional limitations, such as difficulty running short distances. Veterans with burn pit exposures will benefit from physical activity interventions designed to improve functional ability and overall quality of life. Veterans with significant exposure to burn pits during their overseas military service will have a detailed documentation of their limitations and participate in either a 12-week coach-led tele-exercise intervention or standard of care. This project is designed to improve functional mobility and could be implemented for Veterans with burn pit exposure.",[33],[113,114,32],"Exercise","Cardiopulmonary","2025-12-03",{"date":117,"type":45},"2025-12-04",{"date":47,"type":23},{"date":120,"type":23},"2030-12-01",{"name":122,"class":123},"VA Office of Research and Development","FED",1]